> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-70/
- Published: 2022-04-10T12:00:00.000Z
- Updated: 2026-09-14T17:40:00.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140844

**Varian** has acquired privately-held Montreal-based **Evinance Innovation, Inc.**, a clinical decision support software company. The acquisition is expected to expand the capabilities of Varian’s 360 Oncology care management platform by integrating clinical workflow, decision support, and adherence tracking based on leading cancer care guidelines.

**Merck** has agreed to acquire for about $400 million **Viralytics**, an Australian company focused on oncolytic immunotherapy treatments for a range of cancers. The transaction will give Merck full rights to Cavatak (CVA21), an investigational oncolytic immunotherapy designed to infect and kill cancer cells.

**Aesculap, Inc.** has acquired the assets of **Dextera Surgical**, which manufactures and markets proprietary medical devices for surgical procedures, including surgical staplers and devices for coronary artery bypass graft surgery. Aesculap will oversee operations in Redwood City, CA to continue the manufacturing and distribution of Dextera’s products.